Endometrial Cavity Fluid Before Frozen Embryo Transfer: A Critical Review of Prognostic Significance and Evidence for Cycle Cancellation
Year: 2026
Type: review
Abstract: Endometrial cavity fluid during preparation for frozen embryo transfer creates uncertainty about proceeding, reassessing, or deferring treatment. This critical narrative review examines how assessment timing, fluid trajectory, and underlying pathology influence prognosis and the interpretation of cancellation studies. Focused searches were updated through October 20, 2026; this was not a systematic review or meta-analysis. In a cohort of 1034 frozen blastocyst transfers, live birth rates after fluid resolution and without fluid were 35.2% and 34.2%, respectively (adjusted risk ratio 1.00, 95% confidence interval 0.70-1.50). In 4308 single euploid transfers, fluid persisting at the decision for progesterone initiation or ovulation triggering was associated with a lower live birth rate than no fluid (38.3% vs 58.5%; adjusted odds ratio 0.50, 95% confidence interval 0.28-0.88). These assessments are not interchangeable with transfer-day fluid. Subsequent-transfer analyses after cancellation exclude patients who never reach another transfer and cannot establish a cumulative live birth benefit. Deferral can add visits, costs, and distress; any effect on treatment discontinuation or cumulative live birth remains unquantified specifically for cavity fluid. A practical assessment should distinguish resolved fluid, diagnosed tubal or uterine pathology, and persistent unexplained collections. Cause-specific treatment has a different evidence base from empirical aspiration or hormonal changes. No direct randomized comparison of proceeding with vs canceling frozen embryo transfer was identified. Multicenter trials should evaluate cumulative live birth and time to live birth from a common decision point, retaining all assigned patients.
DOI: 10.2147/ijwh.s656172
Authors: Yujie Ma, Jinying Fu
Institution: Henan University of Chinese Medicine
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,836
OpenAlex ID: W7225466449
